A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients	non-small cell lung carcinoma	Active, not recruiting	Phase 2	2025-07-30		NCT05078931

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Merck Sharp & Dohme LLC	650
Shanghai Chest Hospital	116

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University	Shanghai	China	1

Clinical trials